These pre-clinical results are notable. The changes in tumour...

These pre-clinical results are notable. The changes in tumour burden in Figure 2 and Figure 3 really highlight CF33's clinical potential in combination with immune checkpoint inhibitors.

For those interested, here's the images from the peer-reviewed article that Woo et al. (2020) published in the Journal of the American College of Surgeons related to the conference presentation poster. This one had three groups: control (PBS), injected intraperitoneally (IP) or injected intravenously (IV). Survival curves are added as well - note the shorter time period compared to the conference poster.

Figure 4. Significant decrease in peritoneal tumor burden is seen after treatment with CF33-hNIS-antiPDL1. (A) Bioluminescence images ofanimals intraperitoneally implanted with 5 106 AsPC-1-ffluc human pancreatic tumor cells and treated on day 2 with PBS (controls), IV virus(IV), or IP virus (IP). (B) Graphic representation of luminescence data representative of intraperitoneal tumor burden is shown for treatment immediately after tumor implantation (D0; p < 0.001 IP vs other groups) or on day 2 (D2; p < 0.01 PBS vs other groups). Retrieved from Woo et al. (2020).




Figure 5. Early intraperitoneal (IP) treatment with CF33-hNIS-antiPDL1 increases overall survival in a nude mouse model of the human pancreatic cancer cell line - AspC-1-ffluc. Kaplan-Meier survival analysis of the survival of mice with AsPC-1-ffluc peritoneal tumor (5106 cells IP) treated on the same day ([A] D0, and D2 - by either PBS, orCF33-hNIS-antiPDL1, 105 pfu, IP vs IV). Intraperitoneal treatment on D0 and D2 significantly improved survival compared to PBS or IV treatment. Retrieved from Woo et al. (2020).